IT1254314B - Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari. - Google Patents

Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.

Info

Publication number
IT1254314B
IT1254314B ITRM920222A ITRM920222A IT1254314B IT 1254314 B IT1254314 B IT 1254314B IT RM920222 A ITRM920222 A IT RM920222A IT RM920222 A ITRM920222 A IT RM920222A IT 1254314 B IT1254314 B IT 1254314B
Authority
IT
Italy
Prior art keywords
carnitine
acyl
association
ace
treatment
Prior art date
Application number
ITRM920222A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ITRM920222A0 publication Critical patent/ITRM920222A0/it
Priority to ITRM920222A priority Critical patent/IT1254314B/it
Priority to CA002092505A priority patent/CA2092505C/en
Priority to AT93830120T priority patent/ATE165241T1/de
Priority to JP06797193A priority patent/JP3616116B2/ja
Priority to DE69318061T priority patent/DE69318061T2/de
Priority to DK93830120T priority patent/DK0566542T3/da
Priority to EP93830120A priority patent/EP0566542B1/en
Priority to ES93830120T priority patent/ES2116429T3/es
Priority to KR1019930004877A priority patent/KR100244092B1/ko
Publication of ITRM920222A1 publication Critical patent/ITRM920222A1/it
Application granted granted Critical
Publication of IT1254314B publication Critical patent/IT1254314B/it
Priority to US08/612,671 priority patent/US5861434A/en
Priority to HK98109954.8A priority patent/HK1009325B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Viene descritto un nuovo uso terapeutico della L-carnitina e di alcune acil L-carnitine o dei loro sali farmacologicamente accettabili in associazione con ACE-inibitori nel trattamento di patologie cardiovascolari.Adatte composizioni somminitrabili per via orale, parenterale, rettale o transdermica in forma di dosaggio unitario comprendono da circa 0,5 a circa 2 g di L-carnitina o di una quantità equivalente di acil L-carnitina o di un loro sale accettabile e, ad esempio, da circa 5 a circa 20 mg dell'ACE-inibitore lisinopril.
ITRM920222A 1992-03-27 1992-03-27 Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari. IT1254314B (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ITRM920222A IT1254314B (it) 1992-03-27 1992-03-27 Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
CA002092505A CA2092505C (en) 1992-03-27 1993-03-25 Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders
EP93830120A EP0566542B1 (en) 1992-03-27 1993-03-26 Composition comprising L-carnitine or acyl-L-carnitine in combination with an ACE-inhibitor for the treatment of cardiovascular disorders
JP06797193A JP3616116B2 (ja) 1992-03-27 1993-03-26 心臓血管障害の処置のためのａｃｅ阻害剤を配合するｌ−カルニチンまたはアシル−ｌ−カルニチンを含む医薬組成物
DE69318061T DE69318061T2 (de) 1992-03-27 1993-03-26 Zubereitung enthaltend L-Carnitin oder Acyl-L-Carnitin in Kombination mit einem ACE-Inhibitor zur Behandlung von kardiovaskulären Störungen
DK93830120T DK0566542T3 (da) 1992-03-27 1993-03-26 Præparat omfattende L-carnitin eller acyl-L-carnitin i kombination med en ACE-hæmmer til behandling af kardiovaskulære fors
AT93830120T ATE165241T1 (de) 1992-03-27 1993-03-26 Zubereitung enthaltend l-carnitin oder acyl-l- carnitin in kombination mit einem ace-inhibitor zur behandlung von kardiovaskulären störungen
ES93830120T ES2116429T3 (es) 1992-03-27 1993-03-26 Composicion que contiene l-carnitina o acil-l-carnitina en combinacion con un inhibidor de ace para el tratamiento de trastornos cardiovasculares.
KR1019930004877A KR100244092B1 (ko) 1992-03-27 1993-03-27 L-카르니틴 또는 아실l-카르니틴과 ace-억제제를 함유한 심장혈관질환치료용 약제조성물과 그 치료방법
US08/612,671 US5861434A (en) 1992-03-27 1996-03-08 Compositions containing L-carnitine or an acyl L-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders
HK98109954.8A HK1009325B (en) 1992-03-27 1998-08-15 Composition comprising l-carnitine or acyl-l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920222A IT1254314B (it) 1992-03-27 1992-03-27 Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.

Publications (3)

Publication Number Publication Date
ITRM920222A0 ITRM920222A0 (it) 1992-03-27
ITRM920222A1 ITRM920222A1 (it) 1993-09-27
IT1254314B true IT1254314B (it) 1995-09-14

Family

ID=11400880

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920222A IT1254314B (it) 1992-03-27 1992-03-27 Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.

Country Status (10)

Country Link
US (1) US5861434A (it)
EP (1) EP0566542B1 (it)
JP (1) JP3616116B2 (it)
KR (1) KR100244092B1 (it)
AT (1) ATE165241T1 (it)
CA (1) CA2092505C (it)
DE (1) DE69318061T2 (it)
DK (1) DK0566542T3 (it)
ES (1) ES2116429T3 (it)
IT (1) IT1254314B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733911B1 (fr) * 1995-05-09 1998-05-29 Takeda Chemical Industries Ltd Composition pharmaceutique pour maladies renales ou cardio-vasculaires
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1284661B1 (it) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.
DK0951909T4 (da) 1998-03-19 2011-01-24 Sigma Tau Ind Farmaceuti Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
LV12491B (lv) * 1998-10-29 2000-12-20 Ivars KALVI�� Farmaceitiska kompozīcija
AU1294600A (en) * 1998-11-11 2000-05-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
US20030206895A1 (en) * 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
WO2001054677A2 (en) * 2000-01-26 2001-08-02 Warner-Lambert Company Ace inhibitor-vasopressin antagonist combinations
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
CA2681185C (en) * 2007-03-21 2018-05-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
US8154340B2 (en) * 2009-02-18 2012-04-10 Hollinworth Fund, LLC Metamaterial power amplifier systems

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
IT1224795B (it) * 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1240799B (it) * 1990-03-15 1993-12-17 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti 3-metiltiopropionil l-carnitina ad attivita' sul sistema cardiovascolare.
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1248323B (it) * 1991-05-16 1995-01-05 Sigma Tau Ind Farmaceuti Ammidi con amminoacidi naturali di alcanoil l-carnitine quali inibitori della degenerazione neuronale e attivatori dei processi di apprendimento e memorizzazione e per il trattamento del coma e composizioni farmaceutiche comprendenti tali composti
IT1245699B (it) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi

Also Published As

Publication number Publication date
HK1009325A1 (en) 1999-05-28
CA2092505A1 (en) 1993-09-28
JP3616116B2 (ja) 2005-02-02
EP0566542B1 (en) 1998-04-22
US5861434A (en) 1999-01-19
ITRM920222A1 (it) 1993-09-27
DE69318061D1 (de) 1998-05-28
ES2116429T3 (es) 1998-07-16
CA2092505C (en) 2004-06-01
KR100244092B1 (ko) 2000-03-02
KR930019208A (ko) 1993-10-18
DE69318061T2 (de) 1998-08-13
DK0566542T3 (da) 1999-01-04
ITRM920222A0 (it) 1992-03-27
JPH0616570A (ja) 1994-01-25
ATE165241T1 (de) 1998-05-15
EP0566542A1 (en) 1993-10-20

Similar Documents

Publication Publication Date Title
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
AR064895A2 (es) Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina
IT1250691B (it) Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
RU93051537A (ru) Перорально вводимая лекарственная форма
IT1308613B1 (it) Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITBO910112A1 (it) Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
CA2192899A1 (en) Composition containing l-carnitine and hydroxycitric acid
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
ES2114562T3 (es) Forma de dosificacion para distribucion retardada de farmacos.
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
DK0977560T3 (da) Ibuprofen-thioestere som hæmmere af den Nf-kappaB-afhængige dannelse af betændelses og smertemediatorer (CoA-thioestere af arylpropionsyrer, aryleddikesyrer og salicylater som hæmmere af den Nf-kappaB-afhængige dannelse af betændelses og smertemediatorer)
RU2059603C1 (ru) ПРОИЗВОДНЫЕ α -ЗАМЕЩЕННЫХ АРИЛУКСУСНЫХ КИСЛОТ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
ITRM920222A1 (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine in associazione con ace-inibitori per il trattamento di patologie cardiovascolari.
BR9611642A (pt) Compostos composição farmacéutica e processo para a preparação de compostos
FR2618331B1 (fr) Compositions pharmaceutiques utiles pour le traitement de l'uremie
TNSN98088A1 (fr) INHIBITEURS DE FARNESYL- TRANSFERASE EN ASSOCIATION AVEC DES INHIBITEURS DE HMG-CoA-REDUCTASE POUR LE TRAITEMENT DU CANCER.
ES2112555T3 (es) Composiciones farmaceuticas orales solubles en agua que contienen derivado de estrona y sales de calcio.
ITRM920693A1 (it) Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hivsieropositivi.
ITRM950544A0 (it) Uso della l-carnitina di suoi derivati e di loro sali farmaceuticamen-te accettabili in combinazione con farmaci antiretrovirali per ridurrei livelli di ceramide e potenziare l'attivita' di tali farmaci antire-trovirali per il trattamento terapeutico dell'invenzione...
KR910014337A (ko) d-2-(6-메톡시-2-나프릴)-프로피온산의 광학활성 유도체와 이것을 함유한 약제학적 조성물
ES2175086T3 (es) Composiciones farmaceuticas anti-emeticas que contienen metotrimeprazina.
ES2119682B1 (es) Una composicion farmaceutica que contiene delapril y manidipino para el tratamiento de enfermedades cardiovasculares y renales.